Last updated on May 2019

Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF


Brief description of study

The study will assess the safety of different dose regimens of HepaStem in cirrhotic Patients with ACLF or with acute decompensation at risk of developing ACLF up to Day 28 of the active study period.

Clinical Study Identifier: NCT02946554

Find a site near you

Start Over

H pital Beaujon

Clichy, France
0.07miles
  Connect »

H pital Paul Brousse

Villejuif, France
8.92miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.